Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma

Modern Pathology

Volumn 21, Issue 6, 2008, Pages 691-699

  Pallarés, Judit ^a   Velasco, Ana ^a   Eritja, Nuria ^a   Santacana, Maria ^a   Dolcet, Xavier ^a   Cuatrecasas, Miriam ^b   Palomar Asenjo, Victor ^a   Catasús, Lluis ^b   Prat, Jaime ^b   Matias Guiu, Xavier ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Endometrial carcinoma; K RAS; Microsatellite instability; Promoter hypermethylation; RASSF1A; Tissue microarray

Indexed keywords

CYCLIN D1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ARTICLE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; METHYLATION; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CELL PROLIFERATION; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 44349169410     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.38     Document Type: Article

References (30)

1. Bockman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17.
2. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular Pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-577.
3. Catasús L, Machín P, Matias-Guiu X, et al. Microsatellite instability in endometrial carcinomas. Clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29:1160-1164.
4. Bussaglia E, del Rio E, Matias-Guiu X, et al. PTEN mutations in endometrial carcinomas. A molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000;31:312-317.
5. Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma. Hum Pathol 2006;37:1465-1472.
6. Lagarda H, Catasus L, Argüelles RM, et al. k-RAS mutations in endometrial carcinomas with microsatellite instability. J Pathol 2001;193:193-199.
7. Machin P, Catasus L, Pons C, et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 2002;33:206-212.
8. Moreno-Bueno G, Hardisson D, Prat J, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002;21:7981-7990.
9. Prat J, Oliva E, Lerma E, et al. Uterine papillary serous adenocarcinoma. A 10 case study of p53 and c-erbB 2 expression and DNA content. Cancer 1994;74:1778-1783.
10. Dammann R, Schagdarsurengin U, Strunnikova M, et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 2003;18:665-677.
11. Pfeiffer GP, Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochem 2005;70:576-583.
12. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002;21:1381-1390.
13. Esteller M, Catasus L, Matias-Guiu X, et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999;155:1767-1772.
14. Pallares J, Martínez-Guitarte JL, Dolcet X, et al. Abnormalities in NF-kB family and related proteins in endometrial carcinoma. J Pathol 2004;204:569-577.
15. Pallares J, Martínez-Guitarte JL, Dolcet X, et al. Survivin expression in endometrial carcinoma. Int J Gynecol Pathol 2005;24:247-253.
16. Pallares J, Martínez-Guitarte JL, Dolcet X, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma. Mod Pathol 2005;18:719-727.
17. Dolcet X, Llobet D, Pallares J, et al. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 2005;85:885-894.
18. V600E mutations in thyroid tumors. Lab Invest 2005;85:1065-1075.
19. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a Ras-association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-319.
20. Kang S, Lee JM, Jeon ES, et al. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer 2006;119:1316-1321.
21. Pijnenborg JMA, Dam-de Veen GC, Kisters N, et al. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer. Ann Oncol 2007;18:491-497.
22. Rastetter M, Schagdarsurengin U, Lahtz C, et al. Frequent intra-tumoral heterogeneity of promoter hypermethylation in malignant melanoma. Histol Histopathol 2007;22:1005-1015.
23. Van Engeland M, Roemen GM, Brink M, et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 2002;21:3792-3795.
24. Dammann R, Schagdarsurengin U, Liu L, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003;22:3806-3812.
25. Kim DH, Kim JS, Park JH, et al. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. Cancer Res 2003;63:6206-6211.
26. Xing M, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 2004;64:1664-1668.
27. Jo H, Kim JW, Kang GH, et al. Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer. Oncol Res 2006;16:205-209.
28. Liu L, Tommasi S, Lee DH, et al. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 2003;22:8125-8136.
29. Song MS, Song SJ, Ayad NG, et al. The tumor suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004;6:129-137.
30. Fajas L, Paul C, Vié A, et al. Cyclin A is a mediator of p120E4F-dependent cell cycle arrest in G1. Mol Cell Biol 2001;21:2956-2966.